Log In
BCIQ
Print this Print this
 

AR-104 (formerly KBPA104)

  Manage Alerts
Collapse Summary General Information
Company Aridis Pharmaceuticals Inc.
DescriptionHuman IgM mAb against Psuedomonas aeruginosa generated using the MabIgX platform technology
Molecular Target P. aeruginosa LPS serotype O1
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationPseudomonas
Indication DetailsTreat Pseudomonas aeruginosa infections
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today